ZA201306416B - Substituted 6,7-dialkoxy-3-isoquinolinol derivatives as inhibitors of phosphodiesterase 10 (pde10a) - Google Patents

Substituted 6,7-dialkoxy-3-isoquinolinol derivatives as inhibitors of phosphodiesterase 10 (pde10a)

Info

Publication number
ZA201306416B
ZA201306416B ZA2013/06416A ZA201306416A ZA201306416B ZA 201306416 B ZA201306416 B ZA 201306416B ZA 2013/06416 A ZA2013/06416 A ZA 2013/06416A ZA 201306416 A ZA201306416 A ZA 201306416A ZA 201306416 B ZA201306416 B ZA 201306416B
Authority
ZA
South Africa
Prior art keywords
isoquinolinol
pde10a
dialkoxy
phosphodiesterase
inhibitors
Prior art date
Application number
ZA2013/06416A
Other languages
English (en)
Inventor
John E Donello
Rong Yang
Bertrand Leblond
Eric Beausoleil
Anne-Sophie Casagrande
Laurent J R Desire
Matthew P Pando
Cedric Chauvignac
Thierry Taverne
Original Assignee
Allergan Inc
Exonhit Therapeutics Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc, Exonhit Therapeutics Sa filed Critical Allergan Inc
Publication of ZA201306416B publication Critical patent/ZA201306416B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Addiction (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ZA2013/06416A 2011-02-18 2013-08-26 Substituted 6,7-dialkoxy-3-isoquinolinol derivatives as inhibitors of phosphodiesterase 10 (pde10a) ZA201306416B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161444566P 2011-02-18 2011-02-18
PCT/US2012/025731 WO2012112946A1 (en) 2011-02-18 2012-02-17 Substituted 6,7-dialkoxy-3-isoquinolinol derivatives as inhibitors of phosphodiesterase 10 (pde10a)

Publications (1)

Publication Number Publication Date
ZA201306416B true ZA201306416B (en) 2014-04-30

Family

ID=45787353

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2013/06416A ZA201306416B (en) 2011-02-18 2013-08-26 Substituted 6,7-dialkoxy-3-isoquinolinol derivatives as inhibitors of phosphodiesterase 10 (pde10a)

Country Status (15)

Country Link
US (2) US8772316B2 (https=)
EP (1) EP2675791B1 (https=)
JP (1) JP2014510055A (https=)
KR (1) KR20140009372A (https=)
CN (1) CN103476757A (https=)
AU (1) AU2012219316A1 (https=)
BR (1) BR112013021180A2 (https=)
CA (1) CA2827724A1 (https=)
CL (1) CL2013002394A1 (https=)
IL (1) IL228008A0 (https=)
MX (1) MX2013009575A (https=)
RU (1) RU2013142364A (https=)
SG (1) SG192839A1 (https=)
WO (1) WO2012112946A1 (https=)
ZA (1) ZA201306416B (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2827724A1 (en) 2011-02-18 2012-08-23 Allergan, Inc. Substituted 6,7-dialkoxy-3-isoquinolinol derivatives as inhibitors of phosphodiesterase 10 (pde10a)
WO2014071044A1 (en) 2012-11-01 2014-05-08 Allergan, Inc. Substituted 6,7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (pde10a)
US9200016B2 (en) 2013-12-05 2015-12-01 Allergan, Inc. Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A)
JP6272604B2 (ja) * 2013-12-27 2018-01-31 日本サプリメント株式会社 糖取り込み促進剤
CN104370813A (zh) * 2014-10-22 2015-02-25 上海大学 异喹啉-6-甲醛的制备方法
SG11201806416XA (en) 2016-02-12 2018-08-30 Astellas Pharma Inc Tetrahydroisoquinoline derivatives
BR112019010511A2 (pt) 2016-11-23 2019-09-17 Bayer Ag derivados de heterociclo bicíclico fundido como pesticidas
US12234217B2 (en) 2018-12-03 2025-02-25 Fmc Corporation Method for preparing N-phenylpyrazole-1-carboxamides
CN113376287A (zh) * 2021-06-15 2021-09-10 劲牌有限公司 基于高效液相色谱法检测环核苷酸磷酸二酯酶抑制剂活性的方法
PY2501648A (es) 2024-01-12 2025-10-31 Syngenta Crop Protection Ag Nuevos compuestos de carboxamida
WO2026008750A1 (en) 2024-07-05 2026-01-08 Syngenta Crop Protection Ag Novel carboxamide compounds

Family Cites Families (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6548490B1 (en) 1997-10-28 2003-04-15 Vivus, Inc. Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
GB0008694D0 (en) * 2000-04-07 2000-05-31 Novartis Ag Organic compounds
US20030032579A1 (en) 2001-04-20 2003-02-13 Pfizer Inc. Therapeutic use of selective PDE10 inhibitors
DE10130167A1 (de) 2001-06-22 2003-01-02 Bayer Ag Imidazotriazine
WO2003014116A1 (en) 2001-08-06 2003-02-20 Bayer Corporation Pyrrolo[2.1-a]isoquinoline derivatives
US20030114469A1 (en) * 2001-09-27 2003-06-19 Cohen David Saul Combinations
WO2004002484A1 (ja) 2002-06-26 2004-01-08 Kyowa Hakko Kogyo Co., Ltd. ホスホジエステラーゼ阻害剤
DE10230604A1 (de) 2002-07-08 2004-01-29 Bayer Ag Heterocyclisch substituierte Imidazotriazine
DE10230605A1 (de) 2002-07-08 2004-01-29 Bayer Ag Substituierte Imidazotriazine
US20070105840A1 (en) 2003-06-30 2007-05-10 Altana Pharma Ag Pyrrolo-dihydroisoquinoline derivatives as pde10 inhibitors
RS20050945A (sr) 2003-06-30 2008-06-05 Altana Pharma Ag., Novi pirolodihidroizohinolini koji se mogu upotrebiti u tretmanu kancera
EP1651251A4 (en) 2003-07-31 2008-06-18 Bayer Pharmaceuticals Corp METHOD FOR THE TREATMENT OF DIABETES AND RELATED DISEASES USING PDE 10A INHIBITORS
EP1723134A2 (en) 2004-02-18 2006-11-22 Pfizer Products Incorporated Tetrahydroisoquinolinyl derivatives of quinazoline and isoquinoline
EP1755611A1 (en) 2004-06-07 2007-02-28 Pfizer Products Inc. Phosphodiesterase 10 inhibition as treatment for obesity-related and metabolic syndrome-related conditions
US20060019975A1 (en) 2004-07-23 2006-01-26 Pfizer Inc Novel piperidyl derivatives of quinazoline and isoquinoline
CA2578996A1 (en) 2004-09-03 2006-03-16 Memory Pharmaceuticals Corporation 4-substituted 4, 6-dialkoxy-cinnoline derivatives as phospodiesterase 10 inhibitors for the treatment of psychiatric or neurological syndroms
WO2006034491A2 (en) 2004-09-23 2006-03-30 Bayer Pharmaceuticals Corporation Phenyl-substituted quinoline and quinazoline compounds for the treatment of diabetes
US7576080B2 (en) 2004-12-23 2009-08-18 Memory Pharmaceuticals Corporation Certain thienopyrimidine derivatives as phosphodiesterase 10 inhibitors
US20060183763A1 (en) 2004-12-31 2006-08-17 Pfizer Inc Novel pyrrolidyl derivatives of heteroaromatic compounds
KR100896380B1 (ko) 2005-01-07 2009-05-08 화이자 프로덕츠 인코포레이티드 헤테로방향족 퀴놀린 화합물 및 ｐｄｅ10 저해제로서의그의 용도
AU2006218054A1 (en) 2005-01-12 2006-08-31 Nycomed Gmbh Novel pyrrolodihydroisoquinolines as PDE10 inhibitors
CA2595075A1 (en) 2005-01-12 2006-07-20 Matthias Vennemann Pyrrolodihydroisoquinolines as antiproliferative agents
MX2008002207A (es) 2005-08-16 2008-03-27 Memory Pharm Corp Inhibidores de fosfodiesterasa 10.
JP2009524637A (ja) 2006-01-27 2009-07-02 ファイザー・プロダクツ・インク アミノフタラジン誘導体化合物
CA2643963A1 (en) 2006-02-21 2007-08-30 Amgen Inc. Cinnoline derivatives as phosphodiesterase 10 inhibitors
WO2007098214A1 (en) 2006-02-21 2007-08-30 Amgen Inc. Cinnoline derivatives as phosphodiesterase 10 inhibitors
WO2007096743A1 (en) 2006-02-23 2007-08-30 Pfizer Products Inc. Substituted quinazolines as pde10 inhibitors
US20070287707A1 (en) 2006-02-28 2007-12-13 Arrington Mark P Phosphodiesterase 10 inhibitors
US20090099175A1 (en) 2006-03-01 2009-04-16 Arrington Mark P Phosphodiesterase 10 inhibitors
US20070265258A1 (en) 2006-03-06 2007-11-15 Ruiping Liu Quinazoline derivatives as phosphodiesterase 10 inhibitors
WO2007103554A1 (en) 2006-03-08 2007-09-13 Amgen Inc. Quinoline and isoquinoline derivatives as phosphodiesterase 10 inhibitors
TW200817400A (en) 2006-05-30 2008-04-16 Elbion Ag Pyrido [3,2-e] pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them
TW200815436A (en) 2006-05-30 2008-04-01 Elbion Ag 4-amino-pyrido[3,2-e]pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them
US20080090834A1 (en) 2006-07-06 2008-04-17 Pfizer Inc Selective azole pde10a inhibitor compounds
ES2392553T3 (es) * 2006-07-10 2012-12-11 H. Lundbeck A/S Derivados (3-aril-piperazina-1-ilo) de 6,7-dialcoxiquinazolina, 6,7-dialcoxiftalazina y 6,7-dialcoxiisoquinolina
WO2008020302A2 (en) 2006-08-17 2008-02-21 Pfizer Products Inc. Heteroaromatic quinoline-based compounds as phosphodiesterase (pde) inhibitors
CA2663178C (en) 2006-09-11 2016-01-12 Matrix Laboratories Ltd. Dibenzofuran derivatives as inhibitors of pde-4 and pde-10
CN101166128A (zh) 2006-10-16 2008-04-23 琥珀技术有限公司 一种提供第三方服务的方法及相应的系统
US7786139B2 (en) 2006-11-21 2010-08-31 Omeros Corporation PDE10 inhibitors and related compositions and methods
EP2083819B1 (en) 2006-11-21 2017-02-22 Omeros Corporation Pde10 inhibitors and related compositions and methods
US20090062277A1 (en) 2007-08-21 2009-03-05 Essa Hu Phosphodiesterase 10 inhibitors
WO2009025839A2 (en) 2007-08-22 2009-02-26 Amgen Inc. Phosphodiesterase 10 inhibitors
US20090054434A1 (en) 2007-08-23 2009-02-26 Amgen Inc. Isoquinolone derivatives as phosphodiesterase 10 inhibitors
TW200918519A (en) 2007-09-19 2009-05-01 Lundbeck & Co As H Cyanoisoquinoline
EP2227472A1 (en) 2007-11-30 2010-09-15 Elbion Gmbh Aryl and heteroaryl fused imidazo (1,5-a) pyrazines as inhibitors of phosphodiesterase 10
US20090143361A1 (en) 2007-11-30 2009-06-04 Elbion Gmbh Pyrido[3,2-E]Pyrazines, Process For Preparing The Same, And Their Use As Inhibitors Of Phosphodiesterase 10
KR20100110804A (ko) 2007-11-30 2010-10-13 와이어쓰 엘엘씨 포스포디에스테라제 10의 저해물질로서의 아릴 및 헤테로아릴 융합된 이미다조[1,5-ａ]피라진
WO2009143178A2 (en) 2008-05-20 2009-11-26 Omeros Corporation Pde10 inhibitors and related compositions and methods
US8133897B2 (en) 2008-06-20 2012-03-13 H. Lundbeck A/S Phenylimidazole derivatives as PDE10A enzyme inhibitors
TWI501965B (zh) 2008-06-20 2015-10-01 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑之新穎苯基咪唑衍生物
JP2011526294A (ja) 2008-06-25 2011-10-06 エンビボ ファーマシューティカルズ インコーポレイテッド ホスホジエステラーゼ１０阻害剤としての二置換フェニル化合物
BRPI0914772A2 (pt) 2008-06-25 2015-10-20 Envivo Pharmaceuticals Inc compostos heterocíclicos 1,2-dissubstituídos
EP2318410A2 (en) 2008-07-09 2011-05-11 Envivo Pharmaceuticals, Inc. New small-molecule pde-10 inhibitors
AU2009279756B2 (en) 2008-08-05 2015-01-29 Omeros Corporation PDE10 inhibitors and related compositions and methods
MX2011002399A (es) 2008-09-04 2011-04-07 Mitsubishi Tanabe Pharma Corp Compuestos pirimidina tri-sustituida y su uso como inhibidores de fosfodiesterasa 10.
CA2741303A1 (en) 2008-10-28 2010-06-03 Schering Corporation Substituted pyrazoloquinolines and derivatives thereof
WO2010054260A1 (en) 2008-11-07 2010-05-14 Biotie Therapies Gmbh Imidazo[5,1-c][1,2,4]benzotriazine derivatives as inhibitors of phosphodiesterases
WO2010054253A1 (en) 2008-11-07 2010-05-14 Biotie Therapies Gmbh Triazine derivatives as inhibitors of phosphodiesterases
TW201030001A (en) 2008-11-14 2010-08-16 Amgen Inc Pyridine and pyrimidine derivatives as phosphodiesterase 10 inhibitors
SG171954A1 (en) 2008-12-04 2011-07-28 Hoffmann La Roche Pyridazinone derivatives
ES2397934T3 (es) 2008-12-17 2013-03-12 Amgen Inc. Compuestos de aminopiridina y carboxipiridina como inhibidores de fosfodiesterasa 10
AU2010211050B2 (en) 2009-02-05 2016-05-12 Takeda Pharmaceutical Company Limited Pyridazinone compounds
US9187455B2 (en) 2009-02-23 2015-11-17 Hoffmann-La Roche Inc. Substituted pyridazines as PDE10A inhibitors
EP2400991A1 (en) 2009-02-24 2012-01-04 Janssen Pharmaceutica, N.V. Radiolabelled pde10 ligands
US8685967B2 (en) 2009-04-07 2014-04-01 Merck Sharp & Dohme Corp. Substituted triazolopyridines and analogs thereof
CN105125547A (zh) 2009-05-07 2015-12-09 费瑞姆医药有限公司 苯氧基甲基杂环化合物
EP2434885B1 (en) 2009-05-27 2014-03-26 Merck Sharp & Dohme Corp. Alkoxy tetrahydro-pyridopyrimidine pde10 inhibitors
AU2010254149B2 (en) 2009-05-29 2014-08-21 Merck Sharp & Dohme Llc Radiolabeled PDE10 inhibitors
WO2010138585A1 (en) 2009-05-29 2010-12-02 Merck Sharp & Dohme Corp. Pyrimidinones as pde10 inhibitors
TW201111383A (en) 2009-05-29 2011-04-01 Wyeth Llc Substituted imidazo[1,5-a]quinoxalines as inhibitors of phosphodiesterase 10
CA2765750A1 (en) 2009-06-19 2010-12-23 H. Lundbeck A/S Novel phenylimidazole derivative as pde10a enzyme inhibitor
EP2467382B1 (en) 2009-08-17 2014-06-25 Merck Sharp & Dohme Corp. Amino tetrahydro-pyridopyrimidine pde10 inhibitors
PE20121438A1 (es) 2009-09-24 2012-10-26 Hoffmann La Roche Derivados de imidazopiridina o imidazopirimidina como inhibidores de fosfodiesterasa 10a
WO2011053559A1 (en) 2009-10-30 2011-05-05 Merck Sharp & Dohme Corp. Aryl aminopyridine pde10 inhibitors
KR101774035B1 (ko) 2009-10-30 2017-09-01 얀센 파마슈티카 엔.브이. 이미다조［１，２―ｂ］피리다진 유도체 및 ＰＤＥ１０ 저해제로서의 그의 용도
AU2010311493B2 (en) 2009-10-30 2014-06-05 Janssen Pharmaceutica Nv Radiolabelled PDE10 ligands
TWI485151B (zh) 2009-12-17 2015-05-21 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑之雜芳香族苯基咪唑衍生物
TWI481607B (zh) 2009-12-17 2015-04-21 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑的２－芳基咪唑衍生物
TWI487705B (zh) 2009-12-17 2015-06-11 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑之雜芳香族芳基三唑衍生物
TW201200516A (en) 2009-12-17 2012-01-01 Lundbeck & Co As H Phenylimidazole derivatives comprising an ethynylene linker as PDE10A enzyme inhibitors
US8470820B2 (en) 2010-01-22 2013-06-25 Hoffman-La Roche Inc. Nitrogen-containing heteroaryl derivatives
ES2540867T3 (es) 2010-02-26 2015-07-14 Mitsubishi Tanabe Pharma Corporation Compuestos de pirazolopirimidina y su uso como inhibidores de PDE10
JP2011201873A (ja) 2010-03-03 2011-10-13 Mitsubishi Tanabe Pharma Corp 三置換ピリミジン化合物及びそのｐｄｅ１０阻害薬としての使用
AR080754A1 (es) 2010-03-09 2012-05-09 Janssen Pharmaceutica Nv Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10
KR101713453B1 (ko) 2010-03-12 2017-03-07 오메로스 코포레이션 Pde10 억제제 및 관련 조성물 및 방법
US8410117B2 (en) 2010-03-26 2013-04-02 Hoffmann-La Roche Inc. Imidazopyrimidine derivatives
WO2011132048A1 (en) 2010-04-19 2011-10-27 Glenmark Pharmaceutical S.A. Heteroaryl compounds as pde10a inhibitors
WO2011132051A2 (en) 2010-04-19 2011-10-27 Glenmark Pharmaceuticals S.A. Tricycle compounds as phosphodiesterase-10 inhibitors
WO2011138657A1 (en) 2010-05-04 2011-11-10 Glenmark Pharmaceuticals S.A. Aryl substituted olefinic compounds as pde10a inhibitors
JP2013526546A (ja) 2010-05-13 2013-06-24 アムジエン・インコーポレーテツド Ｐｄｅ１０阻害剤としてのヘテロアリ−ルオキシヘテロシクリル化合物
AU2011253058A1 (en) 2010-05-13 2012-12-06 Amgen Inc. Heteroaryloxycarbocyclyl compounds as PDE10 inhibitors
WO2011143365A1 (en) 2010-05-13 2011-11-17 Amgen Inc. Nitrogen heterocyclic compounds useful as pde10 inhibitors
US8969349B2 (en) 2010-05-26 2015-03-03 Sunovion Pharmaceuticals Inc. Substituted quinoxalines and quinoxalinones as PDE-10 inhibitors
US8703768B2 (en) 2010-06-09 2014-04-22 Hoffmann-La Roche Inc. Nitrogen containing heteroaryl compounds
WO2011163355A1 (en) 2010-06-24 2011-12-29 Takeda Pharmaceutical Company Limited Fused heterocyclic compounds as phosphodiesterases (pdes) inhibitors
TW201215607A (en) 2010-07-02 2012-04-16 Lundbeck & Co As H Aryl-and heteroarylamid derivatives as PDE10A enzyme inhibitor
TW201206935A (en) 2010-07-16 2012-02-16 Lundbeck & Co As H Triazolo-and pyrazoloquinazoline derivatives as PDE10A enzyme inhibitor
CA2827724A1 (en) 2011-02-18 2012-08-23 Allergan, Inc. Substituted 6,7-dialkoxy-3-isoquinolinol derivatives as inhibitors of phosphodiesterase 10 (pde10a)
US9200016B2 (en) * 2013-12-05 2015-12-01 Allergan, Inc. Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A)

Also Published As

Publication number Publication date
RU2013142364A (ru) 2015-03-27
US20120214837A1 (en) 2012-08-23
US8772316B2 (en) 2014-07-08
BR112013021180A2 (pt) 2019-09-24
KR20140009372A (ko) 2014-01-22
US20140309253A1 (en) 2014-10-16
EP2675791A1 (en) 2013-12-25
CL2013002394A1 (es) 2014-07-04
US9670181B2 (en) 2017-06-06
CN103476757A (zh) 2013-12-25
EP2675791B1 (en) 2016-02-17
IL228008A0 (en) 2013-09-30
JP2014510055A (ja) 2014-04-24
MX2013009575A (es) 2014-10-14
SG192839A1 (en) 2013-09-30
CA2827724A1 (en) 2012-08-23
AU2012219316A1 (en) 2013-10-03
WO2012112946A1 (en) 2012-08-23

Similar Documents

Publication Publication Date Title
ZA201301951B (en) Benzimidazole derivatives as p13 kinase inhibitors
ZA201306416B (en) Substituted 6,7-dialkoxy-3-isoquinolinol derivatives as inhibitors of phosphodiesterase 10 (pde10a)
ZA201305612B (en) Pyrrolotriazinone derivatives as pi3k inhibitors
ZA201309345B (en) Substituted indazole derivatives active as kinase inhibitors
ZA201402561B (en) Benzonitrile derivatives as kinase inhibitors
IL239193A0 (en) New Benzimidazole Derivatives as Kinase Inhibitors
IL232358A0 (en) Inhibitors of phosphodiesterase type 10a
ZA201401113B (en) COMPOUND AND COMPOSISTIONS AS c-KIT KINASE INHIBITORS
PL2693881T3 (pl) Podstawione analogi N-fenylopirymidyno-2-aminy jako inhibitory kinazy AXL
AP2013007252A0 (en) Heterocyclic compounds as kinase inhibitors
IL221823A (en) Pipridine-4-Il-Aztidine Derivatives as Jack 1 Suppressors
ZA201306545B (en) 6,7-dihydro-pyrazolo[1,5-a]pyrazin-4-ylamine derivatives useful as inhibitors of betasecretase (bace)
IL228103A0 (en) Amino-quinolines as kinase inhibitors
ZA201309150B (en) Derivatives of 1-phenyl-2-pyridinyl- alkyl alcohols as phosphodiesterase inhibitors
IL228949A0 (en) History of pyrazolospiroctone for use as acetyl-CoA carboxylase inhibitors
SI3070091T1 (sl) Derivati benzodioksola kot zaviralci fosfodiesteraze
IL237475A0 (en) Pyrlotriazinone derivatives as pi3k inhibitors
ZA201407695B (en) Triazolo compounds as pde 10 inhibitors
HK1192754A (en) Substituted 6,7-dialkoxy-3-isoquinolinol derivatives as inhibitors of phosphodiesterase 10 (pde10a)